Reneuron Group (RENE)

 

Latest News

ReNeuron updates on ophthalmology programmes

ReNeuron Group has reported very significant positive developments with its retinal disease programme.

ReNeuron updates on clinical strategy in stroke disability

ReNeuron Group says it expects to be able to begin a Phase III study with its CTX cell therapy candidate in stroke disability...

Update on clinical strategy in stroke disability

RNS Number: 9274C ReNeuron Group plc 21 April 2017 AIM: RENE 21 April 2017 ReNeuron Group plc ReNeuron advances global clinical development strategy with cell therapy candidate for stroke disability ReNeuron Group plc (the "Company") (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to provide an update...

Update on progress in ophthalmology programmes

RNS Number: 9273C ReNeuron Group plc 21 April 2017 AIM: RENE 21 April 2017 ReNeuron Group plc ReNeuron successfully develops cryopreserved formulation of its retinal stem cell therapy candidate and expands ophthalmology programmes ReNeuron Group plc (the "Company") (AIM: RENE), a UK-based global leader in the development of cell-based therap...

All News

DateHeadlineSource
21-04-17ReNeuron updates on ophthalmology programmesStockMarketWire
21-04-17ReNeuron updates on clinical strategy in stroke disabilityStockMarketWire
21-04-17Update on clinical strategy in stroke disabilityRNS
21-04-17Update on progress in ophthalmology programmesRNS
01-03-17Block Listing Review and Total Voting RightsRNS
15-02-17ReNeuron featured in BBC documentaryRNS
07-02-17Director Deals - ReNeuron Group PLC (RENE)StockMarketWire
07-02-17Director Share PurchaseRNS
01-02-17ReNeuron Group to present at the Shares Spotlight Evening in Edinburgh on 15 February 2017StockMarketWire
14-12-16Director Share PurchaseRNS
05-12-16ReNeuron widens H1 pretax lossStockMarketWire
05-12-16ReNeuron reports positive results in Phase II Stroke TrialStockMarketWire
05-12-16Reports Positive Results in Phase II Stroke TrialRNS
05-12-16Interim ResultsRNS
14-11-16Notification of Interim ResultsRNS
14-10-16ReNeuron Group Plc to present at the Shares Investor Evening in London on 27th October 2016StockMarketWire
05-10-16Notification of Major Interest in SharesRNS
22-09-16Block Listing Review and Total Voting RightsRNS
06-09-16ReNeuron passes AGM resolutionsStockMarketWire
06-09-16Result of AGMRNS
06-09-16AGM Trading UpdateRNS
05-08-16Posting of Annual Report and Notice of AGMRNS
04-08-16Stroke clinical data published in The LancetRNS
22-07-16Publication of positive pre-clinical retinal dataRNS
20-07-16Directors' Interest in Shares and Share OptionsRNS
07-07-16Preliminary ResultsRNS
14-06-16Notification of Preliminary ResultsRNS
13-06-16Reuron says patient recruitment completed in stroke trial StockMarketWire
13-06-16Patient recruitment completed in stroke trialRNS
09-06-16ReNeuron pursues brain cancer with exosome platform StockMarketWire
09-06-16Pursues brain cancer with exosome platformRNS
08-06-16ReNeuron Group gives Retinitis pigmentosa update StockMarketWire
08-06-16Retinitis pigmentosa update & Notice of KOL eventRNS
31-05-16Change of AdviserRNS
21-03-16Are Today’s Double-Digit Rises Just The Start For Filtronic Plc, Angle plc And ReNeuron Group Plc?Motley Fool
15-03-16RENE says first patient treated in RP clinical trial StockMarketWire
15-03-16First Patient Treated in RP Clinical TrialRNS
23-02-16ReNeuron Relocates to South WalesRNS
17-02-16Director Deals - ReNeuron Group PLC (RENE)StockMarketWire
17-02-16Director Deals - ReNeuron Group PLC (RENE)StockMarketWire

RSS feeds

  • Editorial news feed for LSE:RENE Editorial
  • Regulatory news feed for LSE:RENE Regulatory